The yin and yang of kidney development and Wilms’ tumors

Genes and Development

Volumn 29, Issue 5, 2015, Pages 467-482

  Hohenstein, Peter ^a,b   Pritchard Jones, Kathy ^c   Charlton, Jocelyn ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Kidney development; miRNA; Nephron progenitor cells; Wilms tumor; Wt1; catenin

Indexed keywords

MICRORNA;

CANCER GENETICS; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; EPIGENETICS; GENE; HUMAN; KIDNEY DEVELOPMENT; NEPHROBLASTOMA; NEPHRON; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL PROCESSING; ANIMAL; EMBRYOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KIDNEY; KIDNEY TUMOR; ORGANOGENESIS; PATHOLOGY;

ANIMALS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MICRORNAS; ORGANOGENESIS; WILMS TUMOR;

EID: 84924656280     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.256396.114     Document Type: Review

References (161)

1. Aiden AP, Rivera MN, Rheinbay E, KuM, Coffman EJ, Truong TT, Vargas SO, Lander ES, Haber DA, Bernstein BE. 2010. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell 6: 591–602.
2. Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV, Grundy PE, Leach S, Marra MA, Brooks-Wilson AR, Penninger J, et al. 2004. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms’ tumor versus normal kidney. Hum Mol Genet 13: 2061–2074.
3. Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, Fews GA, Gill H, Gentle D, Shuib S, Ricketts CJ, et al. 2012. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet 44: 277–284.
4. Bahubeshi A, Bal N, Rio Frio T, Hamel N, Pouchet C, Yilmaz A, Bouron-Dal Soglio D, Williams GM, Tischkowitz M, Priest JR, et al. 2010. Germline DICER1 mutations and familial cystic nephroma. J Med Genet 47: 863–866.
5. Bardeesy N, Falkoff D, Petruzzi M-J, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. 1994. Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7: 91–97.
6. Bates CM, Kharzai S, Erwin T, Rossant J, Parada LF. 2000. Role of N-myc in the developing mouse kidney. Dev Biol 222: 317–325.
7. Beckwith JB, Kiviat NB, Bonadio JF. 1990. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms’ tumor. Pediatr Pathol 10: 1–36.
8. Berger AH, Knudson AG, Pandolfi PP. 2011. A continuum model for tumour suppression. Nature 476: 163–169.
9. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, et al. 1990. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60: 509–520.
10. Chang HM, Triboulet R, Thornton JE, Gregory RI. 2013. A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28– let-7 pathway. Nature 497: 244–248.
11. Charlton J, Williams RD, Sebire NJ, Popov S, Vujanic G, Chagtai T, Alcaide-German M, Morris T, Butcher LM, Guilhamon P, et al. 2015. Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour. Genome Medicine 7: 11.
12. Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP, Robertson EJ, Alt FW. 1992. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev 6: 2248–2257.
13. Chau YY, Brownstein D, Mjoseng H, Lee WC, Buza-Vidas N, Nerlov C, Jacobsen SE, Perry P, Berry R, Thornburn A, et al. 2011. Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1. PLoS Genet 7: e1002404.
14. Chilukamarri L, Hancock AL, Malik S, Zabkiewicz J, Baker JA, Greenhough A, Dallosso AR, Huang TH, Royer-Pokora B, Brown KW, et al. 2007. Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. Neoplasia 9: 970–978.
15. Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R. 2011. b-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms’ tumors. Am J Pathol 179: 3045–3055.
16. Costantini F, Kopan R. 2010. Patterning a complex organ: branching morphogenesis and nephron segmentation in kidney development. Dev Cell 18: 698–712.
17. Cotchin E. 1975. Spontaneous tumours in young animals. Proc R Soc Med 68: 653–655.
18. Cox D. 1966. Chromosome constitution of nephroblastomas. Cancer 19: 1217–1224.
19. Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH, Sarkar A, Barasch J, Vuononvirta R, Jones C, et al. 2009. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms’ tumor. PLoS Genet 5: e1000745.
20. Das A, Tanigawa S, Karner CM, Xin M, Lum L, Chen C, Olson EN, Perantoni AO, Carroll TJ. 2013. Stromal–epithelial crosstalk regulates kidney progenitor cell differentiation. Nat Cell Biol 15: 1035–1044.
21. Davies JA, Ladomery M, Hohenstein P, Michael L, Shafe A, Spraggon L, Hastie N. 2004. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet 13: 235–246.
22. Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob- Hirsch J, Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N, et al. 2006. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res 66: 6040–6049.
23. Ding L, Paszkowski-Rogacz M, Nitzsche A, Slabicki MM, Heninger AK, de Vries I, Kittler R, Junqueira M, Shevchenko A, Schulz H, et al. 2009. A genome-scale RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identity. Cell Stem Cell 4: 403–415.
24. Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, et al. 2009. Loss of heterozygosity at 2q37 in sporadic Wilms’ tumor: putative role for miR-562. Clin Cancer Res 15: 5985–5992.
25. Ehrlich M, Hopkins NE, Jiang G, Dome JS, Yu MC, Woods CB, Tomlinson GE, Chintagumpala M, Champagne M, Dillerg L, et al. 2003. Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genet Cytogenet 141: 97–105.
26. Ehrlich D, Bruder E, Thome MA, Gutt CN, von Knebel Doeberitz M, Niggli F, Perantoni AO, Koesters R. 2010. Nuclear accumulation of b-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. Pediatr Dev Pathol 13: 1–8.
27. El-Dahr S, Hilliard S, Aboudehen K, Saifudeen Z. 2014. The MDM2–p53 pathway: multiple roles in kidney development. Pediatr Nephrol 29: 621–627.
28. Essafi A, Webb A, Berry RL, Slight J, Burn SF, Spraggon L, Velecela V, Martinez-Estrada OM, Wiltshire JH, Roberts SG, et al. 2011. A Wt1-controlled chromatin switching mechanism underpins tissue-specific Wnt4 activation and repression. Dev Cell 21: 559–574.
29. Flisikowska T, Kind A, Schnieke A. 2013. The new pig on the block: modelling cancer in pigs. Transgenic Res 22: 673–680.
30. Foulkes WD, Bahubeshi A, Hamel N, Pasini B, Asioli S, Baynam G, Choong CS, Charles A, Frieder RP, Dishop MK, et al. 2011. Extending the phenotypes associated with DICER1 mutations. Hum Mutat 32: 1381–1384.
31. Francke U, Holmes LB, Atkins L, Riccardi VM. 1979. Aniridia- Wilms’ tumor association: evidence for specific deletion of 11p13. Cytogenet Cell Genet 24: 185–192.
32. Frese KK, Tuveson DA. 2007. Maximizing mouse cancer models. Nat Rev Cancer 7: 645–658.
33. Fukuzawa R, Heathcott RW, More HE, Reeve AE. 2007. Sequential WT1 and CTNNB1 mutations and alterations of b-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol 60: 1013–1016.
34. Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE, Robertson SP. 2010. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J Med Genet 47: 791–794.
35. Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy PE, Breslow N, Jennings L, Green DM, Beckwith JB, et al. 2012. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a children’s oncology group study. Neoplasia 14: 742–756.
36. Gao F, Maiti S, Sun G, Ordonez NG, Udtha M, Deng JM, Behringer RR, Huff V. 2004. The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome. Mol Cell Biol 24: 9899–9910.
37. Gebeshuber CA, Kornauth C, Dong L, Sierig R, Seibler J, Reiss M, Tauber S, Bilban M, Wang S, Kain R, et al. 2013. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med 19: 481–487.
38. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. 1990. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774–778.
39. Grill C, Sunitsch S, Hatz M, Hauser-Kronberger C, Leuschner I, Hoefler G, Guertl B. 2011. Activation of b-catenin is a late event in the pathogenesis of nephroblastomas and rarely correlated with genetic changes of the APC gene. Pathology 43: 702–706.
40. Grundy P, Coppes MJ, Haber D. 1995. Molecular genetics of Wilms tumor. Hematol Oncol Clin North Am 9: 1201–1215.
41. Guertl B, Leuschner I, Guelly C, Ebner B, Kronberger C, Hoefler G. 2010. Is predisposition for nephroblastoma linked to polymorphisms of the WTX gene?. Pathol Oncol Res 16: 189–191.
42. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A. 2002. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 11: 651–659.
43. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Ziegler U, Gubler MC, Schedl A. 2001. Two splice variants of the Wilms’ tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 106: 319–329.
44. Hanks S, Perdeaux ER, Seal S, Ruark E, Mahamdallie SS, Murray A, Ramsay E, Del Vecchio Duarte S, Zachariou A, de Souza B, et al. 2014. Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour. Nat Commun 5: 4398.
45. Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, Miyajima K, Timmons CF, Tomlinson GE, Mastrangelo D, et al. 2002. Deregulation of Caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62: 5897–5901.
46. Harari-Steinberg O, Metsuyanim S, Omer D, Gnatek Y, Gershon R, Pri-Chen S, Ozdemir DD, Lerenthal Y, Noiman T, Ben-Hur H, et al. 2013. Identification of human nephron progenitors capable of generation of kidney structures and functional repair of chronic renal disease. EMBO Mol Med 5: 1556–1568.
47. Hard GC. 1985. Differential renal tumor response to N-ethylnitrosourea and dimethylnitrosamine in the Nb rat: basis for a new rodent model of nephroblastoma. Carcinogenesis 6: 1551–1558.
48. Haruta M, Matsumoto Y, Izumi H, Watanabe N, Fukuzawa M, Matsuura S, Kaneko Y. 2008. Combined BubR1 protein down-regulation and RASSF1A hypermethylation in Wilms tumors with diverse cytogenetic changes. Mol Carcinog 47: 660–666.
49. Heo I, Joo C, Kim YK, Ha M, Yoon MJ, Cho J, Yeom KH, Han J, Kim VN. 2009. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 138: 696–708.
50. Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM 3rd, Jaenisch R. 2005. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8: 275–285.
51. Honda A, Hirose M, Sankai T, Yasmin L, Yuzawa K, Honsho K, Izu H, Iguchi A, Ikawa M, Ogura A 2014. Single-step generation of rabbits carrying a targeted allele of the tyrosinase gene using CRISPR/Cas9. Exp Anim doi: 1538/expanim.14-0034.
52. Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V. 2011. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 121: 174–183.
53. Hubertus J, Lacher M, Rottenkolber M, Muller-Hocker J, Berger M, Stehr M, von Schweinitz D, Kappler R. 2011. Altered expression of imprinted genes in Wilms tumors. Oncol Rep 25: 817–823.
54. Hubertus J, Zitzmann F, Trippel F, Muller-Hocker J, Stehr M, von Schweinitz D, Kappler R. 2013. Selective methylation of CpGs at regulatory binding sites controls NNAT expression in Wilms tumors. PLoS ONE 8: e67605.
55. Huff V. 2011. Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11: 111–121.
56. Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, Rao MK. 2010. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 29: 4971–4979.
57. Jaehning JA. 2010. The Paf1 complex: platform or player in RNA polymerase II transcription?. Biochim Biophys Acta 1799: 379–388.
58. Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Minaur S, et al. 2009. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet 41: 95–100.
59. Kaneko Y, Egues MC, Rowley JD. 1981. Interstitial deletion of short arm of chromosome 11 limited to Wilms’ tumor cells in a patient without aniridia. Cancer Res 41: 4577–4578.
60. Karner CM, Das A, Ma Z, Self M, Chen C, Lum L, Oliver G, Carroll TJ. 2011. Canonical Wnt9b signaling balances progenitor cell expansion and differentiation during kidney development. Development 138: 1247–1257.
61. Kim MS, Yoon SK, Bollig F, Kitagaki J, Hur W, Whye NJ, Wu YP, Rivera MN, Park JY, Kim HS, et al. 2010. A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. J Biol Chem 285: 14585–14593.
62. Kim WJ, Rivera MN, Coffman EJ, Haber DA. 2012. The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Mol Cell 45: 587–597.
63. Kispert A, Vainio S, McMahon AP. 1998. Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. Development 125: 4225–4234.
64. Knudson AG Jr, Strong LC. 1972. Mutation and cancer: a model for Wilms’ tumor of the kidney. J Natl Cancer Inst 48: 313–324.
65. Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G, McMahon AP. 2008. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 3: 169–181.
66. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, von Knebel Doeberitz M. 1999. Mutational activation of the b-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res 59: 3880–3882.
67. Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T. 2003. Nuclear accumulation of b-catenin protein in Wilms’ tumours. J Pathol 199: 68–76.
68. Koller K, Das S, Leuschner I, Korbelius M, Hoefler G, Guertl B. 2013. Identification of the transcription factor HOXB4 as a novel target of miR-23a. Genes Chromosomes Cancer 52: 709–715.
69. Kort EJ, Farber L, Tretiakova M, Petillo D, Furge KA, Yang XJ, Cornelius A, Teh BT. 2008. The E2F3–Oncomir-1 axis is activated in Wilms’ tumor. Cancer Res 68: 4034–4038.
70. Koufos A, Grundy P, Morgan K, Aleck KA, Hadro T, Lampkin BC, Kalbakji A, Cavenee WK. 1989. Familial Wiedemann- Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 44: 711–719.
71. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. 1993. WT-1 is required for early kidney development. Cell 74: 679–691.
72. Kusafuka T, Miao J, Kuroda S, Udatsu Y, Yoneda A. 2002. Codon 45 of the b-catenin gene, a specific mutational target site of Wilms’ tumor. Int J Mol Med 10: 395–399.
73. Laurenti E, Wilson A, Trumpp A. 2009. Myc’s other life: stem cells and beyond. Curr Opin Cell Biol 21: 844–854.
74. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. 1995. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375: 34–39.
75. Lemoine NR, Hughes CM, Cowell JK. 1992. Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms’ tumours. J Pathol 168: 237–242.
76. Li D, Qiu Z, Shao Y, Chen Y, Guan Y, Liu M, Li Y, Gao N, Wang L, Lu X, et al. 2013a. Heritable gene targeting in themouse and rat using a CRISPR–Cas system. Nat Biotechnol 31: 681–683.
77. Li W, Teng F, Li T, Zhou Q. 2013b. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR–Cas systems. Nat Biotechnol 31: 684–686.
78. Li F, Cowley DO, Banner D, Holle E, Zhang L, Su L. 2014a. Efficient genetic manipulation of the NOD–Rag1_/_IL2RgCnull mouse by combining in vitro fertilization and CRISPR/Cas9 technology. Sci Rep 4: 5290.
79. Li W, Hartwig S, Rosenblum ND. 2014b. Developmental origins and functions of stromal cells in the normal and diseased mammalian kidney. Dev Dyn 243: 853–863.
80. Lillico SG, Proudfoot C, Carlson DF, Stverakova D, Neil C, Blain C, King TJ, Ritchie WA, Tan W, Mileham AJ, et al. 2013. Live pigs produced from genome edited zygotes. Sci Rep 3: 2847.
81. Ludgate JL, Le Mee G, Fukuzawa R, Rodger EJ, Weeks RJ, Reeve AE, Morison IM. 2013. Global demethylation in loss of imprinting subtype of Wilms tumor. Genes Chromosomes Cancer 52: 174–184.
82. Maiti S, Alam R, Amos CI, Huff V. 2000. Frequent association of b-catenin and WT1 mutations in Wilms tumors. Cancer Res 60: 6288–6292.
83. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, et al. 2007. Wilms tumor suppressor WTX negatively regulates WNT/b-catenin signaling. Science 316: 1043–1046.
84. Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS, et al. 2014. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS ONE 9: e109924.
85. Menke AL, IJpenberg A, Fleming S, Ross A, Medine CN, Patek CE, Spraggon L, Hughes J, Clarke AR, Hastie ND. 2003. The wt1-heterozygous mouse; a model to study the development of glomerular sclerosis. J Pathol 200: 667–674.
86. Metsuyanim S, Pode-Shakked N, Schmidt-Ott KM, Keshet G, Rechavi G, Blumental D, Dekel B. 2008. Accumulation of malignant renal stem cells is associated with epigenetic changes in normal renal progenitor genes. Stem Cells 26: 1808–1817.
87. Metsuyanim S, Harari-Steinberg O, Buzhor E, Omer D, Pode-Shakked N, Ben-Hur H, Halperin R, Schneider D, Dekel B. 2009. Expression of stem cell markers in the human fetal kidney. PLoS ONE 4: e6709.
88. Miller-Hodges E, Hohenstein P. 2012. WT1 in disease: shifting the epithelial–mesenchymal balance. J Pathol 226: 229–240.
89. Miyagawa K, Kent J, Moore A, Charlieu JP, Little MH, Williamson KA, Kelsey A, Brown KW, Hassam S, Briner J, et al. 1998. Loss of WT1 function leads to ectopic myogenesis in Wilms’ tumour. Nat Genet 18: 15–17.
90. Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ, Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A, et al. 2011. The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev Cell 20: 583–596.
91. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F, et al. 2003. Multigene methylation analysis of Wilms’ tumour and adult renal cell carcinoma. Oncogene 22: 6794–6801.
92. Mugrauer G, Alt FW, Ekblom P. 1988. N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization. J Cell Biol 107: 1325–1335.
93. Murphy AJ, Pierce J, de Caestecker C, Libes J, Neblett D, de Caestecker M, Perantoni AO, Tanigawa S, Anderson JR, Dome JS, et al. 2014. Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor. Pediatr Blood Cancer 61: 198–205.
94. Nagalakshmi VK, Ren Q, Pugh MM, Valerius MT, McMahon AP, Yu J. 2011. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int 79: 317–330.
95. Nisen PD, Zimmerman KA, Cotter SV, Gilbert F, Alt FW. 1986. Enhanced expression of the N-myc gene in Wilms’ tumors. Cancer Res 46: 6217–6222.
96. Nishiyama R, Qi L, Lacey M, Ehrlich M. 2005. Both hypomethylation and hypermethylation in a 0.2-kb region of a DNA repeat in cancer. Mol Cancer Res 3: 617–626.
97. Norris MD, Brian MJ, Vowels MR, Stewart BW. 1988. N-myc amplification in Wilms’ tumor. Cancer Genet Cytogenet 30: 187–189.
98. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE. 1993. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature 362: 749–751.
99. Ohlsson R, Cui H, He L, Pfeifer S, Malmikumpu H, Jiang S, Feinberg AP, Hedborg F. 1999. Mosaic allelic insulin-like growth factor 2 expression patterns reveal a link between Wilms’ tumorigenesis and epigenetic heterogeneity. Cancer Res 59: 3889–3892.
100. Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T, et al. 2014. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 156: 663–677.
101. Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, Okita H, Koshinaga T, Oue T, Hinotsu S, et al. 2012. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor. Pediatr Blood Cancer 59: 499–505.
102. Okutsu T, Kuroiwa Y, Kagitani F, Kai M, Aisaka K, Tsutsumi O, Kaneko Y, Yokomori K, Surani MA, Kohda T, et al. 2000. Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms’ tumors. J Biochem 127: 475–483.
103. Ozdemir DD, Hohenstein P. 2014. Wt1 in the kidney—a tale in mouse models. Pediatr Nephrol 29: 687–693.
104. Park S, Bernard A, Bove KE, Sens DA, Hazen-Martin DJ, Garvin AJ, Haber DA. 1993. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms’ tumour. Nat Genet 5: 363–367.
105. Park JS, Ma W, O’Brien LL, Chung E, Guo JJ, Cheng JG, Valerius MT, McMahon JA, Wong WH, McMahon AP. 2012. Six2 and Wnt regulate self-renewal and commitment of nephron progenitors through shared gene regulatory networks. Dev Cell 23: 637–651.
106. Park TS, Lee HJ, Kim KH, Kim JS, Han JY. 2014. Targeted gene knockout in chickens mediated by TALENs. Proc Natl Acad Sci 111: 12716–12721.
107. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, et al. 1991. Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67: 437–447.
108. Perotti D, Hohenstein P, Bongarzone I, Maschietto M, Weeks M, Radice P, Pritchard-Jones K. 2013. Is Wilms tumor a candidate neoplasia for treatment with WNT/b-catenin pathway modulators?—A report from the renal tumors biology-driven drug development workshop. Mol Cancer Ther 12: 2619–2627.
109. Pode-Shakked N, Dekel B. 2011. Wilms tumor–a renal stem cell malignancy? Pediatr Nephrol 26: 1535–1543.
110. Pode-Shakked N, Shukrun R, Mark-Danieli M, Tsvetkov P, Bahar S, Pri-Chen S, Goldstein RS, Rom-Gross E, Mor Y, Fridman E, et al. 2013. The isolation and characterization of renal cancer initiating cells from human Wilms’ tumour xenografts unveils new therapeutic targets. EMBOMolMed 5: 18–37.
111. Preger-Ben Noon E, Barak H, Guttmann-Raviv N, Reshef R. 2009. Interplay between activin and Hox genes determines the formation of the kidney morphogenetic field. Development 136: 1995–2004.
112. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D, et al. 1990. The candidate Wilms’ tumour gene is involved in genitourinary development. Nature 346: 194–197.
113. Prosser HM, Koike-Yusa H, Cooper JD, Law FC, Bradley A. 2011. A resource of vectors and ES cells for targeted deletion of microRNAs in mice. Nat Biotechnol 29: 840–845.
114. Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, Chang TC, Khokhar S, Wickiser JE, Karandikar NJ, Malter JS, et al. 2014. Somatic mutations in DROSHA and DICER1 impair micro- RNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2: 4802.
115. Ripoche MA, Kress C, Poirier F, Dandolo L. 1997. Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. Genes Dev 11: 1596–1604.
116. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, et al. 2007. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315: 642–645.
117. Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, Zhang J, Haber DA. 2009. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci 106: 8338–8343.
118. Ruteshouser EC, Robinson SM, Huff V. 2008. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47: 461–470.
119. Saifudeen Z, Dipp S, Stefkova J, Yao X, Lookabaugh S, El-Dahr SS. 2009. p53 regulates metanephric development. J Am Soc Nephrol 20: 2328–2337.
120. Schell C, Wanner N, Huber TB. 2014. Glomerular development—shaping the multi-cellular filtration unit. Semin Cell Dev Biol 36: 39–49.
121. Schneid H, Vazquez MP, Seurin D, le Bouc Y. 1991. Loss of heterozygosity in non-tumoral tissue in two children with Beckwith-Wiedemann syndrome. Growth Regul 1: 168–170.
122. Schroeder WT, Chao LY, Dao DD, Strong LC, Pathak S, Riccardi V, Lewis WH, Saunders GF. 1987. Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. Am J Hum Genet 40: 413–420.
123. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, Weirich A, Ludwig R, Royer-Pokora B. 1997. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci 94: 3972–3977.
124. Schumacher V, Schuhen S, Sonner S, Weirich A, Leuschner I, Harms D, Licht J, Roberts S, Royer-Pokora B. 2003. Two molecular subgroups of Wilms’ tumors with or without WT1 mutations. Clin Cancer Res 9: 2005–2014.
125. Scott J, Cowell J, Robertson ME, Priestley LM, Wadey R, Hopkins B, Pritchard J, Bell GI, Rall LB, Graham CF, et al. 1985. Insulin-like growth factor-II gene expression in Wilms’ tumour and embryonic tissues. Nature 317: 260–262.
126. Self M, Lagutin OV, Bowling B, Hendrix J, Cai Y, Dressler GR, Oliver G. 2006. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J 25: 5214–5228.
127. Senanayake U, Das S, Vesely P, Alzoughbi W, Frohlich LF, Chowdhury P, Leuschner I, Hoefler G, Guertl B. 2012. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 33: 1014–1021.
128. Sharma PM, Bowman M, Yu BF, Sukumar S. 1994. A rodent model for Wilms tumors: embryonal kidney neoplasms induced by N-nitroso-N9-methylurea. Proc Natl Acad Sci 91: 9931–9935.
129. Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, Tomlinson GE, Mastrangelo D, Pass HI, Brambilla E, et al. 2005. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 113: 600–604.
130. Shukrun R, Pode-Shakked N, Pleniceanu O, Omer D, Vax E, Peer E, Pri-Chen S, Jacob J, Hu Q, Harari-Steinberg O, et al. 2014. Wilms’ tumor blastemal stem cells dedifferentiate to propagate the tumor bulk. Stem Cell Reports 3: 24–33.
131. Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, et al. 2011. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 48: 273–278.
132. Slater RM, de Kraker J. 1982. Chromosome number 11 and Wilms’ tumor. Cancer Genet Cytogenet 5: 237–245.
133. Stark K, Vainio S, Vassileva G, McMahon AP. 1994. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 372: 679–683.
134. Stricker SH, Feber A, Engstrom PG, Caren H, Kurian KM, Takashima Y, Watts C, Way M, Dirks P, Bertone P, et al. 2013. Widespread resetting of DNA methylation in glioblastoma- initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev 27: 654–669.
135. Sun FL, Dean WL, Kelsey G, Allen ND, Reik W. 1997. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 389: 809–815.
136. Szemes M, Dallosso AR, Melegh Z, Curry T, Li Y, Rivers C, Uney J, Magdefrau AS, Schwiderski K, Park JH, et al. 2013. Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A. Hum Mol Genet 22: 74–83.
137. Thornton JE, Chang HM, Piskounova E, Gregory RI. 2012. Lin28-mediated control of let-7 microRNA expression by alternative TUTases Zcchc11 (TUT4) and Zcchc6 (TUT7). RNA 18: 1875–1885.
138. Timp W, Feinberg AP. 2013. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 13: 497–510.
139. Torrezan GT, Ferreira EN, Nakahata AM, Barros BD, Castro MT, Correa BR, Krepischi AC, Olivieri EH, Cunha IW, Tabori U, et al. 2014. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat Commun 5: 4039.
140. Udtha M, Lee SJ, Alam R, Coombes K, Huff V. 2003. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms’ tumors. Oncogene 22: 3821–3826.
141. Urbach A, Yermalovich A, Zhang J, Spina CS, Zhu H, Perez- Atayde AR, Shukrun R, Charlton J, Sebire N, Mifsud W, et al. 2014. Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev 28: 971–982.
142. Vesselinovitch SD, Koka M, Rao KV, Mihailovich N, Rice JM. 1977. Prenatal multicarcinogenesis by ethylnitrosourea in mice. Cancer Res 37: 1822–1828.
143. Visvader JE. 2011. Cells of origin in cancer. Nature 469: 314–322.
144. Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton D, Schofield PN, Reik W, Latif F, et al. 2002. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms’ tumour and colorectal cancer. Oncogene 21: 7277–7282.
145. Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen Q-R, Hsu CH, Yan C, et al. 2015. Recurrent DGCR8, DROSHA, and SIX homeodomainmutations in favorable histology Wilms tumors. Cancer Cell 27: 286–297.
146. Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, Boccon-Gibod L, Graf N, Pritchard-Jones K, O’Sullivan M. 2013. miRNA profiles as a predictor of chemoresponsiveness in Wilms’ tumor blastema. PLoS ONE 8: e53417.
147. Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M. 2009. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer 48: 1102–1111.
148. Wegert J, Ishaque N, Vardapour R, Georg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, et al. 2015. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27: 298–311.
149. Wilkins RJ. 1988. Genomic imprinting and carcinogenesis. Lancet 1: 329–331.
150. Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, et al. 2010. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms’ tumor. Clin Cancer Res 16: 2036–2045.
151. Williams RD, Chagtai T, Alcaide-German M, Apps J, Wegert J, Popov S, Vujanic G, Van Tinteren H, van den Heuvel-Eibrink MM, Kool M, et al. 2015. Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget (in press).
152. Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, Albrecht S, Von Schweinitz D, Pietsch T. 2003. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms’ tumors. Lab Invest 83: 429–434.
153. Wu MK, Sabbaghian N, Xu B, Addidou-Kalucki S, Bernard C, Zou D, Reeve AE, Eccles MR, Cole C, Choong CS, et al. 2013. Biallelic DICER1 mutations occur in Wilms tumours. J Pathol 230: 154–164.
154. Xin Z, Soejima H, Higashimoto K, Yatsuki H, Zhu X, Satoh Y, Masaki Z, Kaneko Y, Jinno Y, Fukuzawa R, et al. 2000. A novel imprinted gene, KCNQ1DN, within the WT2 critical region of human chromosome 11p15.5 and its reduced expression in Wilms’ tumors. J Biochem 128: 847–853.
155. Xu PX. 2013. The EYA–SO/SIX complex in development and disease. Pediatr Nephrol 28: 843–854.
156. Xu PX, Zheng WM, Huang L, Maire P, Laclef C, Silvius D. 2003. Six1 is required for the early organogenesis of mammalian kidney. Development 130: 3085–3094.
157. Xu B, Zeng D-q, Wu Y, Zheng R, Gu L, Lin X, Hua X, Jin G-H. 2011. Tumor suppressor menin represses paired box gene 2 expression via Wilms tumor suppressor protein-polycomb group complex. J Biol Chem 286: 13937–13944.
158. Xu J, Wong EM, Cheng C, Li J, Sharkar MTK, Xu CY, Chen B, Sun J, Jing D, Xu PX. 2014. Eya1 interacts with Six2 and Myc to regulate expansion of the nephron progenitor pool during nephrogenesis. Dev Cell 31: 434–447.
159. Yang D, Xu J, Zhu T, Fan J, Lai L, Zhang J, Chen YE. 2014. Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. J Mol Cell Biol 6: 97–99.
160. Zhang X, Xing G, Saunders GF. 1999. Proto-oncogene N-myc promoter is down regulated by the Wilms’ tumor suppressor gene WT1. Anticancer Res 19: 1641–1648.
161. Zitzmann F, Mayr D, Berger M, Stehr M, von Schweinitz D, Kappler R, Hubertus J. 2014. Frequent hypermethylation of a CTCF binding site influences Wilms tumor 1 expression in Wilms tumors. Oncol Rep 31: 1871–1876.